JP2017535551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535551A5 JP2017535551A5 JP2017526138A JP2017526138A JP2017535551A5 JP 2017535551 A5 JP2017535551 A5 JP 2017535551A5 JP 2017526138 A JP2017526138 A JP 2017526138A JP 2017526138 A JP2017526138 A JP 2017526138A JP 2017535551 A5 JP2017535551 A5 JP 2017535551A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- vegf
- compound
- stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014904606A AU2014904606A0 (en) | 2014-11-17 | Method of treating or preventing stroke | |
| AU2014904606 | 2014-11-17 | ||
| PCT/AU2015/050720 WO2016077878A1 (en) | 2014-11-17 | 2015-11-17 | Method of treating or preventing stroke |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535551A JP2017535551A (ja) | 2017-11-30 |
| JP2017535551A5 true JP2017535551A5 (https=) | 2018-12-06 |
| JP6863892B2 JP6863892B2 (ja) | 2021-04-21 |
Family
ID=56012959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526138A Active JP6863892B2 (ja) | 2014-11-17 | 2015-11-17 | 脳卒中を治療又は予防する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10336821B2 (https=) |
| EP (1) | EP3220952B1 (https=) |
| JP (1) | JP6863892B2 (https=) |
| KR (1) | KR102560025B1 (https=) |
| CN (1) | CN107106681B (https=) |
| AU (1) | AU2015349610B2 (https=) |
| CA (1) | CA2967070C (https=) |
| DK (1) | DK3220952T3 (https=) |
| ES (1) | ES2881303T3 (https=) |
| PL (1) | PL3220952T3 (https=) |
| RU (1) | RU2744909C2 (https=) |
| WO (1) | WO2016077878A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2718326B1 (en) | 2011-06-13 | 2020-08-19 | CSL Limited | Antibodies against g-csfr and uses thereof |
| US10617756B2 (en) * | 2017-01-05 | 2020-04-14 | Shimojani, LLC | Drug regimen for treatment of cerebral ischemia |
| WO2019055589A1 (en) * | 2017-09-13 | 2019-03-21 | The Regents Of The University Of Michigan | INHIBITION OF PROTEIN KINASE C TO EXTEND THE TREATMENT OF THE TISSUE ACTIVATOR OF PLASMINOGEN FOR ISCHEMIC DISEASE |
| US20210179721A1 (en) * | 2017-11-29 | 2021-06-17 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
| US12281160B2 (en) | 2018-03-23 | 2025-04-22 | Csl Limited | Method of treating asthma |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| US12583929B2 (en) | 2020-06-04 | 2026-03-24 | CSL Innovation Pty Ltd | Method of treating acute respiratory distress syndrome |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| IL325176A (en) | 2023-07-05 | 2026-02-01 | CSL Innovation Pty Ltd | Methods for treating or preventing a complication of sickle cell disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232439A1 (en) | 2002-06-17 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of VEGF-B expression |
| AU2005269265B2 (en) | 2004-08-02 | 2012-01-12 | Zenyth Operations Pty Ltd | A method of treating cancer comprising a VEGF-B antagonist |
| NZ612578A (en) * | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| PL2018184T3 (pl) | 2006-05-17 | 2013-12-31 | The Ludwig Institute For Cancer Res | Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego |
| US20110318365A1 (en) * | 2007-09-15 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Methods for treatment of degenerative disease associated with apoptosis |
| AU2009233718A1 (en) * | 2008-04-09 | 2009-10-15 | Ludwig Institute For Cancer Research | Regulation of fatty acid transporters |
| JP5823671B2 (ja) * | 2009-07-27 | 2015-11-25 | 国立大学法人 新潟大学 | 免疫製剤を含む脳梗塞治療用医薬品組成物 |
| RU2718054C2 (ru) | 2013-11-28 | 2020-03-30 | СиЭсЭл ЛИМИТЕД | Способ лечения нефропатии |
| WO2015089585A1 (en) | 2013-12-18 | 2015-06-25 | Csl Limited | Method of treating wounds |
-
2015
- 2015-11-17 CN CN201580073640.8A patent/CN107106681B/zh active Active
- 2015-11-17 AU AU2015349610A patent/AU2015349610B2/en active Active
- 2015-11-17 WO PCT/AU2015/050720 patent/WO2016077878A1/en not_active Ceased
- 2015-11-17 EP EP15861231.7A patent/EP3220952B1/en active Active
- 2015-11-17 ES ES15861231T patent/ES2881303T3/es active Active
- 2015-11-17 JP JP2017526138A patent/JP6863892B2/ja active Active
- 2015-11-17 KR KR1020177016154A patent/KR102560025B1/ko active Active
- 2015-11-17 DK DK15861231.7T patent/DK3220952T3/da active
- 2015-11-17 CA CA2967070A patent/CA2967070C/en active Active
- 2015-11-17 PL PL15861231T patent/PL3220952T3/pl unknown
- 2015-11-17 RU RU2017120031A patent/RU2744909C2/ru active
- 2015-11-17 US US15/527,066 patent/US10336821B2/en active Active
-
2019
- 2019-05-14 US US16/411,321 patent/US10961304B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535551A5 (https=) | ||
| RU2017120031A (ru) | Способ лечения или предотвращения инсульта | |
| JP2019523295A5 (https=) | ||
| JP2017506626A5 (https=) | ||
| CN106170496B (zh) | 针对纤连蛋白-eda的免疫球蛋白样分子 | |
| CN113677706B (zh) | 肝毒性的治疗 | |
| JP2017507657A5 (https=) | ||
| RU2018135371A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| JP2019528306A5 (https=) | ||
| JP2018529661A5 (https=) | ||
| EP4309734A1 (en) | Methods for treating cardiovascular disease | |
| US20250075005A1 (en) | Use of alpha-enolase antagonist in treating of fibrotic diseases | |
| JP2021501138A (ja) | 虚血性再灌流障害を治療するための酸化特異的エピトープの阻害 | |
| US20180264108A1 (en) | Immunoglobulin-like molecules directed against fibronectin-eda | |
| TWI566780B (zh) | 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途 | |
| US20230049147A1 (en) | Anti-il-36r antibodies for the treatment of a fibrotic condition | |
| WO2022218908A1 (en) | Mfap4 and treatment of fibrosis | |
| JP7565607B2 (ja) | 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト | |
| Wang et al. | Emerging Role of CXCR4 in Fibrosis | |
| AR130862A1 (es) | Composiciones de anticuerpos anti-tslp y usos de las mismas | |
| WO1999058150A1 (en) | Preventives/remedies for hepatic cirrhosis | |
| NZ777273B2 (en) | Factor XI antibodies and methods of use | |
| EA047713B1 (ru) | Лечение гепатотоксичности | |
| RU2019129858A (ru) | Методы профилактики и лечения сердечных заболеваний | |
| RU2020142517A (ru) | Антитела к фактору xi и способы их применения |